OR WAIT null SECS
Through the acquisition, Aceto can now offer its customers support throughout the drug development process and access to North American manufacturing for APIs and advanced intermediates.
Aceto, a provider of specialty materials for life sciences and advanced technology markets, announced on June 2, 2021 that it has acquired Cascade Chemistry, a US-based manufacturer of active pharmaceutical ingredients (APIs), regulatory starting materials, and advanced intermediates.
Through the acquisition, Aceto can now offer its customers support throughout the drug development process and access to North American manufacturing for APIs and advanced intermediates, Aceto said in a company press release.
“The acquisition of Cascade Chemistry supports and complements our focus on acquisitions that offer customers supply chain choice and technical expertise. With each of our acquisitions, Aceto looks to add companies that enhance our business capabilities and support our growth strategy, while aligning with our core business values,” said Gilles Cottier, CEO of Aceto, in the press release. “We aim to ensure that all our customers have access to robust solutions that are tailored to their needs and allow them to advance their compounds into clinical trials with confidence and efficiency. Cascade Chemistry is an excellent addition to the Aceto team.”
“Cascade Chemistry has a 40-year track record of applying our deep expertise to solve problems and provide our customers with the support they need to successfully complete the challenging and complex API development cycle,” added Jeremiah Marsden, president of Cascade Chemistry, in the press release. “We are proud of our reputation for quality and outstanding customer service and we welcome the opportunity to now join forces with Aceto. Access to the expanded capabilities of the Aceto family of companies will allow us to serve our clients with comprehensive, fully integrated support teams and additional service options that will further enhance and accelerate our clients’ programs.”